VACCINE TRIALS IN MACAQUES WITH VACCINIA-SIV RECOMBINANTS

使用牛痘-SIV 重组体在猕猴中进行疫苗试验

• 批准号: 3791214
• 负责人: RONALD C DESROSIERS
• 金额: --
• 依托单位: THERION BIOLOGICS CORPORATION
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3791214
• 关键词: CD8 molecule; HIV infections; Macaca mulatta; active immunization; biological products; cellular immunity; cytotoxic T lymphocyte; enzyme linked immunosorbent assay; genetic manipulation; human immunodeficiency virus 1; humoral immunity; laboratory mouse; lymphocyte; simian AIDSs; simian immunodeficiency virus; vaccinia virus; viral vaccines; virus antigen

The goal of this program is to develop an effective vaccine against human immunosuppressive virus (HIV-1) infection and the resultant Acquired Immunodeficiency Syndrome (AIDS). The strategy is twofold: (1) to utilize recombinant vaccinia viruses expressing HIV-1 or Simian Immunodeficiency Virus (SIV) antigens to induce immunity, and (2) to utilize the SIV model for evaluation of different recombinant vaccine prototypes as a indicator for corresponding recombinant HIV-1 vaccine performance. Evaluation of recombinant SIV and HIV-1 vaccines will include determination of: vaccine antigenicity in various laboratory animal species (including primates by determination of humoral and cell- mediated immune responses; protective immunity and meliorative properties of recombinant vaccines in primates before and after challenge with SIV: toxicity of vaccinia vectors in SIV-infected primates; safety evaluation in primates of final HIV-1 vaccine candidates. Research assigned to this specific Research Project as a part of the National Cooperative Vaccine Development Group for the Acquired Immunodeficiency Syndrome (NCVDG) will be performed at EG&G Mason Research Institute (EG&G MRI), the New England Regional Primate Research Center (NERPRC), and the University of Massachusetts Medical School (UMMS). This research will be coordinated by the Project Leader at EG&G MRI, Worcester, MA in collaboration with research and administrative support provided by the Principal Investigator at Applied bioTechnology, Cambridge, MA.

该计划的目标是开发一种有效的疫苗， 人类免疫抑制病毒（HIV-1）感染及其结果 获得性免疫缺陷综合症（艾滋病）。 该战略是 （1）利用重组牛痘病毒， HIV-1或猿猴免疫缺陷病毒（SIV）抗原诱导 免疫力，（2）利用SIV模型进行评估， 不同的重组疫苗原型作为 相应的重组HIV-1疫苗性能。 重组SIV和HIV-1疫苗的评价将包括 各种实验动物疫苗抗原性测定 物种（包括灵长类动物，通过测定体液和细胞- 介导的免疫应答;保护性免疫和改善性免疫 重组疫苗在灵长类动物中的特性 SIV攻击：SIV感染的牛痘载体的毒性 灵长类动物;最终HIV-1疫苗在灵长类动物中的安全性评价 候选人 分配给该特定研究项目的研究，作为 国家获得性免疫缺陷病毒疫苗开发合作小组 免疫缺陷综合征（NCVDG）将在EG&G Mason进行 研究所（EG&G MRI），新英格兰地区灵长类动物 研究中心（NERPRC）和马萨诸塞州大学 医学院（UMMS）。 这项研究将由 EG&G MRI（Worcester，MA）项目负责人，与 校长提供的研究和行政支助 应用生物技术研究员，剑桥，MA。